Overview and Scope
Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.
Sizing and Forecast
The respiratory disease vaccine market size has grown steadily in recent years. It will grow from $68.4 billion in 2023 to $69.99 billion in 2024 at a compound annual growth rate (CAGR) of 2.3%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, growing demand for effective and more tolerable vaccines.
The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $76.18 billion in 2028 at a compound annual growth rate (CAGR) of 2.1%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, investments in vaccine, pandemic preparedness. Major trends in the forecast period include innovative vaccines, collaborative research, advancement in vaccine development, drug approval.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Segmentation & Regional Insights
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
2) By Infection: COVID-19; Influenza; Respiratory Syncytial Virus (RSV); Pneumonia; Other Infections
3) By Age: Infant; Adolescent; Adult
4) By End-User: Clinic; Hospital; Other End-Users
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp
Major Driver Impacting Market Growth
The increasing incidence of tuberculosis is expected to propel the growth of the respiratory disease vaccine market going forward. Tuberculosis (TB) is a type of respiratory disease caused by the bacterium Mycobacterium tuberculosis, which primarily affects the lungs and potentially impacts other organs and systems in the body, leading to various complications. The increasing incidence of tuberculosis can catalyze efforts to develop and distribute respiratory disease vaccines to reduce the spread of tuberculosis. For instance, in October 2022, according to the Global Tuberculosis Report published by the World Health Organization, a Switzerland-based global health agency, the global incidence of tuberculosis (TB) was estimated at 10.6 million cases, with a rate of 134 cases per 100,000 population in 2021, an increase of 4.5% from 10.1 million in 2020. Therefore, the increasing incidence of tuberculosis will drive the respiratory disease vaccine market.
Key Industry Players
Major players in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
The respiratory disease vaccine market report table of contents includes:
- Executive Summary
- Travel Arrangement And Reservation Services Market Characteristics
- Travel Arrangement And Reservation Services Market Trends And Strategies
- Travel Arrangement And Reservation Services Market – Macro Economic Scenario
- Global Travel Arrangement And Reservation Services Market Size and Growth
.
.
.
- Global Travel Arrangement And Reservation Services Market Competitive Benchmarking
- Global Travel Arrangement And Reservation Services Market Competitive Dashboard
- Key Mergers And Acquisitions In Travel Arrangement And Reservation Services Market
- Travel Arrangement And Reservation Services Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- Pfizer Inc.
- Johnson & Johnson Ltd.
- Merck & Co. Inc
- Sanofi SA
- AstraZeneca PLC
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
